Enrolling by invitation NCT07307833

Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience

— Observational Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: Non-Interventional Study.
Who it may be relevant to: Registry conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm. Basic parameters: from 18 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: United States
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

This study evaluates the impact of immunotherapy on balance in patients receiving immunotherapy as part of their standard of care.

Change in clinically significant vestibulopathy - vestibular function [Time frame: Baseline, 3 months, 6 months, 12 months]
Change in clinically significant vestibulopathy - hearing level [Time frame: Baseline,12 months]
Oscillopsia Severity Questionnaire (OSQ) [Time frame: Baseline, 3 months, 6 months, 12 months]

At least 18 years of age at screening
Patients who will be initiating single agent immunotherapy with pembrolizumab, cemiplimab, nivolumab, atezolizumab, or dual therapy with (Ipilimumab/Nivolumab or Nivolumab/Relatlimab)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

United States · 1 center

NCT: NCT07307833 · MC250709 · NCI-2025-08558 · 22-009510 · MC250709